Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir
    Sponsors: Pfizer
    Not yet recruiting

  2. Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: Post-COVID / Long-COVID; POST-Covid 19; Post COVID Syndrome; Post-COVID Condition
    Interventions: Other: Standard rehabilitation plus cold water hydrotherapy; Other: Standard rehabilitation only
    Sponsors: Schön Klinik Berchtesgadener Land; Bavarian Health and Food Safety Authority (LGL)
    Not yet recruiting

  3. Spatiotemporal Associations Between the COVID-19 Pandemic and Cancer Diagnoses in Bavaria

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Cancer
    Sponsors: Bavarian Cancer Registry; Ludwig-Maximilians - University of Munich
    Not yet recruiting

  4. Mindmatters: Tutoring and Counseling Program

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Mental Health Issues
    Interventions: Other: Tutoring and Counselling (1); Other: Tutoring and Counselling (2)
    Sponsors: Education University of Hong Kong
    Completed

  5. Posture and Pain Measurements in Post-COVID-19

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19 Respiratory Infection
    Interventions: Other: Physical evaluations of post-COVID-19 individuals
    Sponsors: Izmir Democracy University
    Completed

  6. Attention, Memory and Quality of Life in Post-COVID-19 Adults

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome; Long COVID; Brain Fog
    Interventions: Behavioral: qEEG-neurofeedback; Behavioral: SHAM qEEG-neurofeedback
    Sponsors: Jade Carvalho Da Silva; Santos Dumont Institute
    Not yet recruiting

  7. Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Schizophrenia and Schizoaffective Disorder; Bipolar Disorder (BD)
    Sponsors: Peking University
    Completed

  8. Long COVID Cutaneous Signatures: An ARPA Funded Research Project

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Acute COVID-19; Postural Orthostatic Tachycardia Syndrome (POTS); Diabetic Neuropathy
    Sponsors: CND Life Sciences
    Recruiting

  9. Impact of Balance Training in Community-Dwelling Older Adults After Recovery From COVID-19

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Community-dwelling Older Adults
    Interventions: Other: The Biodex training; Other: Traditional balance training
    Sponsors: Cairo University; Batterjee Medical College
    Recruiting

  10. Effectiveness of Exercise and Physical Activity in Individuals.

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: Thoracic expansion exercises; Other: Physical activity counseling
    Sponsors: Gulsah Bargi
    Completed

  11. Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrome.

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Postural Orthostatic Tachycardia Syndrome (POTS); Post-acute COVID-19 Syndromes
    Interventions: Device: TVNS + Slow-Paced Breathing (TVNS+SDB); Device: TVNS without Breathing Training (TVNS+NB); Device: Sham TVNS + SDB; Device: Sham TVNS + NB
    Sponsors: Ali Kapan
    Not yet recruiting

  12. Vagus Nerve Stimulation to the Ear to Improve Symptoms in Post-COVID-19 and ME/CFS

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Post-COVID / Long-COVID; ME/CFS
    Interventions: Device: transcutaneous vagus nerve stimulation; Device: transcutaneous vagus nerve stimulation
    Sponsors: University of Luxembourg
    Recruiting

  13. Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: ALG-097558; Drug: Dabigatran; Drug: Itraconazole; Other: Placebo
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  14. A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection; COVID-19; COVID-19 Infection; Coronavirus Disease 2019 (COVID-19); COVID-19 (Coronavirus Disease 2019); COVID-19 Vaccination; COVID-19 Vaccines; SARS-CoV-2 Infection, COVID19; SARS-CoV-2 Infection, COVID-19
    Interventions: Drug: BNT162b2
    Sponsors: Pfizer
    Active, not recruiting

  15. PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Post Acute Sequelae of COVID-19
    Interventions: Drug: 11C-PS13
    Sponsors: National Institute of Mental Health (NIMH)
    Recruiting

  16. Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Post COVID-19 Condition
    Interventions: Procedure: Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 2 weeks; Procedure: Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) - 4 weeks
    Sponsors: Mayo Clinic
    Recruiting

  17. NE3107 in Adults With Neurological Symptoms of Long COVID

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Drug: NE3107; Drug: Placebo
    Sponsors: BioVie Inc.
    Recruiting

  18. Secondary Databased Post-marketing Surveillance Study of BNT162b2

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; SARS-CoV-2
    Interventions: Biological: Tozinameran (BNT162b2); Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1); Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
    Sponsors: Pfizer
    Completed

  19. Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Musculoskeletal Pain
    Interventions: Other: Neuromodulation group; Other: Neuromodulation sham group
    Sponsors: University of Alcala
    Recruiting

  20. Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated; Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
    Sponsors: Pfizer; CVS Caremark
    Active, not recruiting

  21. A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19 SARS-CoV-2 Infection
    Interventions: Drug: ibuzatrelvir; Drug: placebo
    Sponsors: Pfizer
    Recruiting

  22. A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV2; COVID-19
    Interventions: Biological: VXA-CoV2-3.1; Biological: COMIRNATY®; Biological: VXA-CoV2-3.3
    Sponsors: Vaxart
    Recruiting

  23. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Recruiting

  24. Probiotic Use for Recovery Enhancement From Long COVID-19

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome
    Interventions: Drug: Probiotic Agent; Other: Placebo
    Sponsors: Rush University Medical Center
    Enrolling by invitation

  25. Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Pneumonia, Community-Acquired; COVID-19 Pneumonia; Cardiovascular Diseases
    Interventions: Other: Blood samples and Oropharyngeal swab; Other: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

  26. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: PASC Post Acute Sequelae of COVID-19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  27. COVID-19 Self-testing IMPROVE

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: IMPROVE
    Sponsors: Temple University; National Institute on Minority Health and Health Disparities (NIMHD)
    Completed

  28. RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Behavioral: Personalized Cardiopulmonary Rehabilitation; Other: Education
    Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  29. RECOVER-SLEEP: Platform Protocol

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Long COVID-19; Hypersomnia; Sleep Disturbance
    Interventions: Drug: Modafinil; Drug: Modafinil Placebo; Drug: Solriamfetol; Drug: Solriamfetol Placebo; Drug: Melatonin; Drug: Melantonin Placebo; Device: Tailored lighting (TL) Active; Device: Tailored lighting (TL) Placebo
    Sponsors: Duke University
    Recruiting

  30. Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome; Lung Disease With Polymyositis; Fibrosis; Lung Diseases, Interstitial; Lung; Disease, Interstitial, With Fibrosis
    Interventions: Drug: Longidaza®; Drug: Placebo
    Sponsors: NPO Petrovax
    Completed

  31. Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: Sedation Complication; Acute Respiratory Distress Syndrome Due to COVID-19; Anesthesia Awareness
    Interventions: Procedure: Depth of sedation monitoring
    Sponsors: Tepecik Training and Research Hospital
    Completed

  32. Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV 2 Pneumonia
    Interventions: Drug: Calcifediol
    Sponsors: Complejo Hospitalario Universitario de Albacete
    Completed

  33. Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: SARS CoV 2 Infection
    Interventions: Biological: IMNN-101
    Sponsors: Imunon
    Active, not recruiting

  34. SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations During COVID-19

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Anxiety; COVID-19 Pandemic
    Interventions: Behavioral: Mindfulness
    Sponsors: University of North Carolina, Chapel Hill; National Institute on Minority Health and Health Disparities (NIMHD); RTI International
    Suspended

  35. Quality of Life After Hyperbaric Oxygen Therapy in Post-COVID Patients

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Long COVID-19 Syndrome; Long Covid19; Long Covid 19
    Interventions: Other: Hyperbaric oxygen therapy
    Sponsors: Rutger Lalieu
    Active, not recruiting

  36. Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: Fever After Vaccination; Fever; Seizures Fever
    Interventions: Biological: mRNA COVID-19 Vaccine; Biological: Routine Childhood Vaccinations
    Sponsors: Duke University; Kaiser Permanente; Columbia University; Children's Hospital Medical Center, Cincinnati; Centers for Disease Control and Prevention
    Active, not recruiting

  37. Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Influenza; COVID-19
    Interventions: Biological: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster); Biological: Sequential Vaccination (Influenza vaccine then mRNA COVID booster); Biological: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
    Sponsors: Duke University; Centers for Disease Control and Prevention; Arizona State University; University Hospitals Cleveland Medical Center; University of Pittsburgh; Washington University School of Medicine; Valleywise Health; Cleveland VA Medical Center; Senders Pediatrics
    Completed

  38. A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Covid-19
    Interventions: Drug: nirmatrelvir, ritonavir
    Sponsors: Pfizer
    Completed

  39. Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: SARS-CoV-2 Subunit Recombinant Protein Vaccine
    Sponsors: PT Bio Farma
    Completed

  40. Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Drug: S-217622; Drug: Placebo
    Sponsors: Shionogi
    Completed

  41. Effects of an Active Coping Program in Patients With Persistent Post-Covid Pain.

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Long COVID; Pain
    Interventions: Behavioral: Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE); Behavioral: Active Comparator: Usual treatment
    Sponsors: University of Valladolid
    Completed

  42. A Study on Paxlovid Once in the Market, to Observe Its Safety and Effectiveness in Patients Who Have a High Chance of Getting Severe COVID-19

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: Pfizer
    Recruiting

  43. Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; Post-Acute COVID-19 Syndrome
    Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine
    Sponsors: Pfizer
    Active, not recruiting

  44. Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: AZD3152; Other: Placebo
    Sponsors: AstraZeneca
    Completed

  45. Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: mHealth Outreach; Other: Care Coordination
    Sponsors: University of California, San Diego; San Ysidro Health Center
    Enrolling by invitation

  46. Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: SARS-CoV-2 subunit protein recombinant vaccine
    Sponsors: PT Bio Farma; Universitas Padjadjaran
    Completed

  47. Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Post-COVID ME/CFS
    Interventions: Drug: Vericiguat Oral Tablet
    Sponsors: Charite University, Berlin, Germany; Bayer
    Recruiting

  48. Fatigability in Long COVID-19

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: Minimal-Dose Home-Based Resistance Exercise
    Sponsors: VA Office of Research and Development
    Recruiting

  49. Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: SARS CoV 2 Infection; COVID-19
    Interventions: Diagnostic Test: Humoral immunity
    Sponsors: Maria Goossens; Université Libre de Bruxelles; Institute of Tropical Medicine; Mensura EDPB; Erasme University Hospital
    Active, not recruiting

  50. Intervention to Prevent Behavioral Health Symptoms Among Pandemic Affected Children

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Emotional Distress; Prosocial Behavior; Pandemic, COVID-19; Coping Skills; Social Support
    Interventions: Behavioral: JoH-C19; Behavioral: Switch off Get Active
    Sponsors: University of Illinois at Urbana-Champaign; Save the Children; Care Connections Mental Wellness and Learning Center; Dickinson Independent School District; Bay District Schools; University of Houston; Baylor College of Medicine; University of South Florida; National Institute of Mental Health (NIMH); Coalition for Compassionate Schools; Boys and Girls Club of Manatee County; Communities in Schools of Galveston County; Communities in Schools Palm Beach; Communities in Schools Gulf South; R'Club Child Care Inc.; Boys and Girls Clubs of Tampa Bay
    Recruiting

  51. SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection); COVID-19
    Interventions: Drug: Bemnifosbuvir (BEM); Drug: Placebo
    Sponsors: Atea Pharmaceuticals, Inc.
    Completed

  52. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Shionogi Protease Inhibitor (S-217622); Drug: placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  53. Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: Respiratory Infection; Pneumonia; Community-acquired Pneumonia; Acute Respiratory Distress Syndrome; COVID-19; Viral Pneumonia; Bacterial Pneumonia; Fungal Pneumonia
    Interventions: Drug: Trimodulin; Drug: Placebo (human albumin 1%)
    Sponsors: Biotest
    Terminated

  54. Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: SARS-CoV-2 subunit protein recombinant vaccine; Biological: Active Comparator
    Sponsors: PT Bio Farma; Universitas Padjadjaran; Udayana University
    Completed

  55. Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Heart Disease
    Sponsors: National Human Genome Research Institute (NHGRI)
    Completed

  56. Mobile Peer Support for OUD Recovery

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Opioid Use Disorder
    Interventions: Behavioral: Mobile Phone App
    Sponsors: Brown University; National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA); Indiana University
    Recruiting

  57. COVID-19 Experiences in the SELF Cohort

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Enrolling by invitation

  58. COVID-19 Vaccine Responses in PIDD Subjects

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: X-linked Agammaglobulinemia; XLA; Primary Immune Deficiency; CVID; Common Variable Immunodeficiency; Primary Antibody Deficiencies; Secondary Hypogammaglobulinemia
    Sponsors: Duke University; Jeffrey Modell Foundation; University of North Carolina, Chapel Hill; University of South Florida; National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

  59. A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Drug: S-217622; Drug: Placebo
    Sponsors: Shionogi; National Institute of Allergy and Infectious Diseases (NIAID)
    Completed

  60. A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Myocarditis
    Interventions: Diagnostic Test: Cardiac Imaging
    Sponsors: Pfizer; Carelon Research; National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  61. Health System Methods to Improve Nursing Retention Amidst Ongoing COVID-19 Pandemic: a Mixed Method Study

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: Motivational Factors for Nurse Retention; Nurse Well-being
    Sponsors: Poudre Valley Health System
    Enrolling by invitation

  62. Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: Bioavailability
    Interventions: Drug: PF-07321332/ritonavir; Drug: PF-07321332/ritonavir; Drug: PF-07321332/ritonavir; Drug: PF-07321332/ritonavir; Drug: PF-07321332
    Sponsors: Pfizer
    Completed

  63. Endothelial Protection in Convalescent COVID-19 Patients

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Endothelial Dysfunction; Inflammation; Thrombosis; COVID-19
    Interventions: Drug: Sulodexide
    Sponsors: Pirogov Russian National Research Medical University
    Terminated

  64. REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Critical Illness; ICU Acquired Weakness; PICS; Cardiorespiratory Fitness
    Interventions: Behavioral: REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)
    Sponsors: Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Vanderbilt University Medical Center; Ohio State University; University of Kentucky; University of Alabama at Birmingham; Florida Atlantic University
    Recruiting

  65. Conversations You Want About Corona Virus Disease (COVID-19)

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Covid19
    Sponsors: Wake Forest University Health Sciences
    Recruiting

  66. Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: Liver Diseases; Alcohol Use Disorder
    Interventions: Behavioral: Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use; Other: Usual Care (UC)
    Sponsors: University of California, San Francisco; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Active, not recruiting

  67. A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV-2 Infection
    Interventions: Biological: COVID-HIG
    Sponsors: Emergent BioSolutions; United States Department of Defense
    Completed

  68. Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Chronic Liver Failure; Cirrhosis, Liver; Portal Hypertension; Liver Transplant Disorder
    Interventions: Diagnostic Test: COVID-19 serosurvey
    Sponsors: Post Graduate Institute of Medical Education and Research, Chandigarh
    Completed

  69. Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

    Tue, 03 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Vaccination; Healthy Volunteer
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  70. A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Upper Respiratory Infection; Lower Respiratory Infection
    Interventions: Device: Fitbit; Device: Douglas Bag; Device: Periflux 6000 EPOS; Device: BIOPAC; Device: Flowmet; Device: NIRS
    Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  71. Korea Comirnaty Post-marketing Surveillance

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Vaccines; Adverse Effects; SARS-CoV-2; Safety
    Interventions: Biological: Tozinameran 12 Years of age and older; Biological: Tozinameran 5 to 11 Years of age; Biological: Tozinameran 6 months to 4 years of age; Biological: Riltozinameran 12 Years of age and older; Biological: Famtozinameran 12 Years of age and older; Biological: Famtozinameran 5 to 11 Years of age; Biological: Raxtozinameran 12 years of age and older; Biological: Raxtozinameran 6 months to 4 years of age
    Sponsors: Pfizer
    Active, not recruiting

  72. Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Vaccine Refusal; Covid19
    Interventions: Behavioral: COVID-19 Individual Awareness and Education.; Behavioral: COVID-19 Community Outreach & Health Promotion.; Behavioral: COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.; Biological: Pop-up community vaccination sites
    Sponsors: Britt Skaathun; San Ysidro Health Center; National Institute on Minority Health and Health Disparities (NIMHD)
    Completed

  73. Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: COVID-19 Vaccine; Breastmilk
    Interventions: Other: Vaccinated Pregnant or Lactating persons
    Sponsors: Deborah O'Connor; University of Toronto; Sinai Health System
    Completed

  74. A Scalable Psychological Intervention to Reduce Psychological Distress Among Healthcare Workers

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Psychological Distress; Depression; Anxiety
    Interventions: Behavioral: Doing What Matters (DWM); Behavioral: Problem Management Plus (PM+); Behavioral: Psychological First Aid (PFA)
    Sponsors: Instituto de Investigación Hospital Universitario La Paz; Universidad Autonoma de Madrid; Hospital Universitario La Paz; Parc Sanitari Sant Joan de Déu; Fundació Sant Joan de Déu; European Commission; VU University of Amsterdam; World Health Organization
    Completed

  75. The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Chlorhexidine digluconate, povidone iodine
    Sponsors: King Abdulaziz University
    Completed

  76. Outpatient Treatment With Anti-Coronavirus Immunoglobulin

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: COVID; SARS-CoV2 Infection; Covid19
    Interventions: Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Other: Placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
    Recruiting

  77. Cellular Senescence and COVID-19 Long-Hauler Syndrome

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV2 Infection
    Sponsors: Mayo Clinic
    Active, not recruiting

  78. Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19)

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: Cardiovascular Diseases; Endothelial Dysfunction
    Interventions: Biological: COVID-19 vaccine; Biological: Concentrate beetroot Juice; Biological: Nitrate-deplete beetroot juice
    Sponsors: Queen Mary University of London
    Recruiting

  79. A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute on Aging (NIA)
    Recruiting

  80. Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine; Biological: BNT162b2 BA.4/5 bivalent; Biological: XBB.1.5-adapted vaccinated
    Sponsors: Pfizer
    Recruiting

  81. National Project on Vaccines, COVID-19 and Frail Patients

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Solid Tumor; Hematologic Diseases; Neurologic Disorder; Rheumatic Diseases
    Interventions: Biological: COVID-19 vaccines
    Sponsors: Azienda USL Reggio Emilia - IRCCS; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Istituto Clinico Humanitas; IRCCS San Raffaele; Regina Elena Cancer Institute; Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS; University of Roma La Sapienza; Fondazione IRCCS Policlinico San Matteo di Pavia; Istituti Fisioterapici Ospitalieri; Istituto Tumori Giovanni Paolo II, BARI; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Completed

  82. A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Biological: mRNA-1273; Biological: Placebo; Biological: mRNA-1273.214
    Sponsors: ModernaTX, Inc.
    Completed

  83. Expressive Writing for the Management of Stress in Cancer Survivors

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions: Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
    Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
    Recruiting

  84. A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: COVID-HIGIV; Other: Placebo (saline)
    Sponsors: Emergent BioSolutions; United States Department of Defense
    Completed

  85. COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: Aerobic Exercise Training; Other: Education
    Sponsors: National Institutes of Health Clinical Center (CC)
    Active, not recruiting

  86. Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

    Fri, 13 Jun 2025 04:00:00 -0000

    Conditions: Post-Coronavirus Disease 19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  87. Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute on Aging (NIA)
    Active, not recruiting

  88. An Observational Study of Neurologic Function After COVID-19 Infection

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Completed

  89. A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: ATI-450; Drug: Placebo
    Sponsors: University of Kansas Medical Center
    Completed

  90. Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Tocilizumab; Drug: Tocilizumab; Other: Standard of Care; Other: Standard of Care
    Sponsors: University of Chicago
    Terminated

  91. Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Sars-CoV2; Breastmilk
    Interventions: Other: Human milk donors
    Sponsors: Deborah O'Connor; University of Toronto; Sinai Health System
    Completed

  92. Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: SARS-CoV2; Breastmilk
    Interventions: Other: COVID-19
    Sponsors: Deborah O'Connor; University of Toronto; Sinai Health System
    Completed

  93. Implications of Covid-19 on the Lifestyle Changes

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: Azienda USL Reggio Emilia - IRCCS
    Completed

  94. Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

    Tue, 10 Jun 2025 04:00:00 -0000

    Conditions: Acute and Long Term Effects of COVID-19 on Systemic Inflammation; Acute and Long Term Effects of COVID-19 on Lung Function; Acute and Long Term Effects of COVID-19 on Cardiac Function; Acute and Long Term Effects of COVID-19 on Kidney Function; Acute and Long Term Effects of COVID-19 on Brain Function
    Sponsors: National Institutes of Health Clinical Center (CC)
    Completed

  95. A Study of N-acetylcysteine in Patients With COVID-19 Infection

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Covid-19
    Interventions: Drug: N-acetylcysteine; Other: Peripheral Blood
    Sponsors: Memorial Sloan Kettering Cancer Center
    Active, not recruiting

  96. Genetics of COVID-19 Susceptibility and Manifestations

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Coronavirus 2019
    Sponsors: National Human Genome Research Institute (NHGRI)
    Suspended

  97. Long-term Impact of Infection With Novel Coronavirus (COVID-19)

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: COVID
    Sponsors: University of California, San Francisco
    Recruiting

  98. A Study to Explore the Role of Gut Flora in COVID-19 Infection

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: Gut Microbiome; Gastrointestinal Microbiome; COVID; COVID-19; Corona Virus Infection; Coronavirus; Coronaviridae Infections; Coronavirus 19; Coronavirus-19; COVID 19
    Interventions: Other: There is no intervention in this study
    Sponsors: ProgenaBiome
    Recruiting

  99. CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection

    Fri, 06 Jun 2025 04:00:00 -0000

    Conditions: Corona Virus Infection
    Interventions: Drug: Anakinra
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Completed

  100. A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

    Thu, 05 Jun 2025 04:00:00 -0000

    Conditions: COVID-19; Coronavirus Infection; Sars-CoV2; Corona Virus Infection; COVID; Coronavirus; Coronavirus-19; Coronavirus 19
    Interventions: Drug: Hydroxychloroquine; Dietary Supplement: Vitamin C; Dietary Supplement: Vitamin D; Dietary Supplement: Zinc
    Sponsors: ProgenaBiome; DSCS CRO
    Completed

  101. CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Corona Virus Infection
    Interventions: Drug: Tocilizumab
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Completed

  102. Longitudinal Population-based Observational Study of COVID-19 in the UK Population

    Sun, 08 Jun 2025 04:00:00 -0000

    Conditions: COVID-19
    Sponsors: Queen Mary University of London; King's College London; London School of Hygiene and Tropical Medicine; University of Edinburgh; Swansea University; Queen's University, Belfast; Barts & The London NHS Trust
    Recruiting

  103. Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI

    Thu, 12 Jun 2025 04:00:00 -0000

    Conditions: Corona Virus Infection
    Interventions: Drug: Sarilumab
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Completed

  104. Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

    Wed, 11 Jun 2025 04:00:00 -0000

    Conditions: Covid19
    Interventions: Biological: COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
    Sponsors: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; UnitedHealthcare
    Active, not recruiting

  105. Viral Infections in Healthy and Immunocompromised Hosts

    Wed, 04 Jun 2025 04:00:00 -0000

    Conditions: Anogenital Herpes; COVID-19; Herpes Labialis
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting